Usefulness of Serum Biomarkers of Endothelial Glycocalyx Damage in Prognosis of Decompensated Patients with Heart Failure with Reduced Ejection Fraction
Section snippets
Methods
We included 3 cohorts of adult participants (age 18 years or older) that were prospectively recruited with clinical data and biospecimens available for this analysis: (1) non-HF − participants recruited in the Cleveland Heart and Metabolic Prevention Study (NCT03012022) and found to have no cardiovascular diseases by electrocardiography and echocardiography; (2) CHF - ambulatory HF with reduced ejection fraction (HFrEF) patients (left ventricular ejection fraction [LVEF] ≤40%) with no
Results
A total of 51 non-HF, 66 ADHF, and 72 patients with CHF were examined for demographic, clinical, and laboratory data (Table 1). There were no differences in median age across groups, but the number of male patients was higher within HF cohorts, especially in ADHF. Patients with ADHF had lower body mass indices and lower blood pressure than CHF despite the similar prevalence of co-morbidities and echocardiographic measurements. There was a weak correlation between serum syndecan-1 and heparan
Discussion
Our present study examines the role of eCG components – syndecan-1, heparan sulfate, and hyaluronic acid – and their value as a potential prognostic marker for patients with CHF and ADHF. All 3 components were elevated in patients with CHF and ADHF. Using median as cut-off values, elevated serum syndecan-1 and heparin sulfate levels were significantly associated with a lower survival rate. Moreover, a doubling of heparan sulfate was also associated with increased mortality. These findings
Disclosures
Dr. Tang is a consultant for Sequana Medical A.G., Cardiol Therapeutics Inc, Genomics plc, and Zehna Therapeutics, and has received an honorarium from Springer Nature for authorship/editorship and American Board of Internal Medicine for exam writing committee participation - all unrelated to the subject and contents of this paper. All other authors have no conflicts of interest to declare.
References (30)
- et al.
Syndecans in wound healing, inflammation, and vascular biology
Int J Biochem Cell Biol
(2007) - et al.
Syndecan-1 as an independent risk factor for the incidence of adverse cardiovascular events in patients having stage C and D heart failure with non-ischemic dilated cardiomyopathy
Clin Chim Acta
(2019) - et al.
Heart failure biomarkers in patients with dilated cardiomyopathy
Int J Cardiol
(2013) - et al.
Predictive value of serial assessment of endothelial function in chronic heart failure
Int J Cardiol
(2012) - et al.
Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface
Arterioscler Thromb Vasc Biol
(2003) - et al.
The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis
Nat Med
(2012) - et al.
Capillary endothelial surface layer selectively reduces plasma solute distribution volume
Am J Physiol Heart Circ Physiol
(2000) - et al.
Fibrosis marker Syndecan-1 and outcome in patients With heart failure With reduced and preserved ejection fraction
Circ Heart Fail
(2014) - et al.
Neurohormonal and clinical sex differences in heart failure
Eur Heart J
(2013) - et al.
Optimizing clinical use of biomarkers in high-risk acute heart failure patients
Eur J Heart Fail
(2016)
Syndecan-1 in acute decompensated heart failure - association with renal function and mortality
Circ J
Endovascular shedding markers in patients with heart failure with reduced ejection fraction: results from a single-center exploratory study
Microcirculation
Syndecan-1 amplifies angiotensin II-induced cardiac fibrosis
Hypertension
Syndecan-4 protects the heart from the profibrotic effects of thrombin-cleaved osteopontin
J Am Heart Assoc
Increased expression of Syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction
Circulation
Cited by (3)
Reply: miRNAs, Endothelin-1 and Endothelial Glycocalyx Disorders in Shock Severity in Postoperative Cardiac Surgery Patients
2024, Journal of the American College of CardiologyBiomarkers of Endothelial Glycocalyx Integrity for Cardiovascular Events in Individuals Without Cardiovascular Disease
2023, Journal of Cardiovascular Translational ResearchMolecular Mechanisms and Therapeutic Implications of Endothelial Dysfunction in Patients with Heart Failure
2023, International Journal of Molecular Sciences
This study was supported by the Collins Family Fund and the Wortzman Family Fund.